Clinical trial · no report yet · Phase 2/Phase 3
NCT05218499
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
- NCT05218499 ↗
- Completed
- Boehringer Ingelheim
- 25 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| X threads | 10 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma
- Phase
- Phase 2/Phase 3
- Status
- Completed
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- Brigimadlin; Doxorubicin
- Arms
- Brigimadlin 30 mg q3w · Experimental
- Brigimadlin 45 mg q3w · Experimental
- Doxorubicin · Active comparator
- Enrollment
- 400
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 31, 2022
- Primary completion
- Apr 16, 2024
- Results posted
- Yes
- Registry record
- NCT05218499 · updated Mar 2, 2026
Publications
linked from the registry- Schoffski P, Lahmar M, Lucarelli A, Maki RG. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future Oncol. 2023 Mar;19(9):621-629. doi: 10.2217/fon-2022-1291. Epub 2023 Mar 29. PubMed 36987836